Tissue Regenix wins purchasing contract from US healthcare firm

Medical devices company Tissue Regenix has won a purchasing contract from US healthcare firm Premier.

The company's subsidiary Tissue Regenix Wound Care secured a group purchasing organisation (GPO) contract from Premier through its DermaPure product under a ‘breakthrough technology agreement awarded by the GPO after a review.

The four step review process will assess whether the technology offers unique attributes to other treatments.

Premier’s 3,600 US hospitals and 12,000 other healthcare providers will now have access to DermaPure through the GPO.

Chief executive Antony Odell said: "Approval under Premier's ‘breakthrough technology agreement’ marks a significant milestone for DermaPure. This confirms the unique characteristics of our patented dCELL technology, the powerful clinical evidence we have collected, and the remarkable outcomes it achieves in real world clinical situations."

The AIM-listed decellularisation technology, dCELL, removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which is not rejected by the patient's body, which can be used to repair diseased or worn out body parts.

Shares in Tissue Regenix were up 2.86% to 18p at 0820 GMT.